Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Inclusion Criteria:

- Adults ≥18 to ≤80 years of age

- History of T2DM for at least 6 months prior to screening

- Moderate to severe renal impairment and not actively on dialysis

- Willing and able to perform self-monitoring of blood glucose

- Willing and able to provide written informed consent

Exclusion Criteria:

- History of type 1 diabetes mellitus, diabetic ketoacidosis (within the previous 6
months), or diabetes resulting from pancreatic disorder or secondary diabetes (from
acromegaly and/or Cushing's disease)

- Subjects who have received a renal allograft

- Subjects expecting to require dialysis or to undergo kidney transplantation within 3
months of study dosing

- Presence of active hepatic disease or clinically significant abnormal liver function
tests at Screening or planned study Day -1

- Subjects with a history of heart attack, severe/unstable angina, or coronary
revascularization procedure within 6 months prior to study Day -2

- History of clinically significant cardiac arrhythmias within 1 year prior to study
Day -2

- Subjects with congestive heart failure

- Subjects with uncontrolled Stage III hypertension

- History of 2 or more emergency room visits, doctors' visits, or hospitalizations due
to hypoglycemia within the 6 months prior to planned study Day -2

- History of alcohol or illicit drug abuse within 1 year prior to Screening

- History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

- Major surgery within 6 months prior to planned study Day -2

- History of any malignancy within the last 5 years

- Triglycerides >1000 mg/dL at Screening or planned study Day -1

- History of any serious adverse reaction or hypersensitivity to an SGLT inhibitor

- Use of corticosteroids within 2 weeks prior to study Day 1

- Use of any investigational drug within 30 days prior to study Day 1, or
investigational protein or antibodies within 60 days of Day 1

- Positive urine pregnancy test at Screening

- Positive urine screen for illicit drug abuse at Screening

- Prior exposure to LX4211